The agency is proposing to reduce the production amount of five opioids, including oxymorphone, fentanyl, hydrocodone, hydromorphone and oxycodone, which were subject to greater scrutiny after the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act was passed last year.
Combined with morphine, the proposal would lead to a 53 percent decrease in the allowable amount of these opioids since 2016, according to Drug Topics.
Read the full report here.
More articles on pharmacy:
Florida compounding facility recalls all human and animal drugs for lack of sterility
Despite ‘Right-to-try’ law, drugmakers still prefer FDA review, GAO finds
Opioid settlements may mean big tax breaks for Big Pharma
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
